drugset / Trial / NCT00683722

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722

Phase 2 Completed 62 enrolled Mesoblast, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).

Timeline

Start
2008-03-20
Primary completion
2009-03-09
Completion
2010-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Prochymal® Cell therapy 1e+08 cells Intravenous